<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131025">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781377</url>
  </required_header>
  <id_info>
    <org_study_id>1632/08 COET</org_study_id>
    <nct_id>NCT01781377</nct_id>
  </id_info>
  <brief_title>Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.</brief_title>
  <official_title>Randomized Controlled Trial of Prophylactic Subhypnotic Propofol vs Metoclopramide and in Combination Therapy for the Prevention of Nausea and Vomiting During Subarachnoid Anesthesia for Cesarean Section.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative nausea and vomiting may occur in 50-80% of patients undergoing cesarean
      section.

      Metoclopramide is a well known Dopamine receptor antagonist that acts at the Chemoreceptor
      trigger zone and  is used effectively for the prevention and treatment of nausea and
      vomiting. Propofol can antagonize Serotonin receptors in the area postremal and is
      associated to a reduced incidence of  postoperative nausea and vomiting. Some studies have
      shown that propofol can prevent intraoperative nausea and vomiting during cesarean section.

      The control of risk factors and the pharmacological prophylaxis of nausea and vomiting
      reduces effectively their incidence.

      In this randomized, double blind, case-control study the efficacy of propofol alone,
      metoclopramide alone and in combination in controlling nausea and vomiting were compared. A
      risk factor control strategy was associated to each study group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>NAUSEA AND VOMITING ASSOCIATED WITH CESAREAN SECTION MEASURED WITH VAS</measure>
    <time_frame>FROM ANESTHESIA TO THE END OF SURGERY (AVERAGE 2 HOURS)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>INCIDENCE OF NAUSEA AND VOMITING</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADVERSE EVENTS</measure>
    <time_frame>FROM ANESTHESIA TO THE END OF SURGERY (AVERAGE 2 HOURS)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HEADACHE, AGITATION, SEDATION.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>PREGNANCY</condition>
  <arm_group>
    <arm_group_label>PROPOFOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>METOCLOPRAMIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL &amp; METOCLOPRAMIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SALINE INFUSION</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROPOFOL</intervention_name>
    <description>PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS</description>
    <arm_group_label>PROPOFOL</arm_group_label>
    <arm_group_label>PROPOFOL &amp; METOCLOPRAMIDE</arm_group_label>
    <other_name>PROPOFOL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>METOCLOPRAMIDE</intervention_name>
    <description>METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS</description>
    <arm_group_label>METOCLOPRAMIDE</arm_group_label>
    <arm_group_label>PROPOFOL &amp; METOCLOPRAMIDE</arm_group_label>
    <other_name>METOCLOPRAMIDE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>SALINE INFUSION</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        CESAREAN SECTION WITHOUT MATERNAL OR FETAL SUFFERING

        American Society of Anesthesiologists score I-II

        36 TO 41 WEEK OF GESTATION

        BMI &lt; 35

        HEMOGLOBIN &gt; 10 mg/dl

        NO COMPLICATIONS (GESTATIONAL DIABETES, COLESTASIS)

        NO ACUTE OR CHRONIC GASTROINTESTINAL DISORDERS

        NO SMOKING OR DRUG ABUSE DURING PREGNANCY

        NO PREVIOUS MAJOR ABDOMINAL SURGERY

        NO PREVIOUS COMPLICATED PREGNANCIES

        FETAL WEIGHT &gt; 2.5 kg

        Exclusion Criteria:

        EMERGENCY CESAREAN SECTION WITH MATERNAL OR FETAL SUFFERING

        American Society of Anesthesiologists score III-IV-V

        &lt; 36 OR &gt; 41 WEEK OF GESTATION

        BMI &gt; 35

        HEMOGLOBIN &lt; 10 mg/dl

        COMPLICATIONS (GESTATIONAL DIABETES, COLESTASIS)

        ACUTE OR CHRONIC GASTROINTESTINAL DISORDERS

        SMOKING OR DRUG ABUSE DURING PREGNANCY

        PREVIOUS MAJOR ABDOMINAL SURGERY

        PREVIOUS COMPLICATED PREGNANCIES

        FETAL WEIGHT &lt; 2.5 kg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZHIRAJR MOKINI, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera San Gerardo di Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FLAVIA PETRINI, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Chieti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MICHELE SCESI, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Chieti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. SS.ma Annunziata</name>
      <address>
        <city>Chieti</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Gerardo di Monza</investigator_affiliation>
    <investigator_full_name>Zhirajr Mokini</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>NAUSEA</keyword>
  <keyword>VOMITING</keyword>
  <keyword>CESAREAN SECTION</keyword>
  <keyword>PREVENTION</keyword>
  <keyword>PROPOFOL</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
